Last reviewed · How we verify
Relafen
At a glance
| Generic name | Relafen |
|---|---|
| Sponsor | Dr. Reddy's Laboratories Limited |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- Cardiovascular Risk Nonsteroidal anti-inflammatory drugs (NSAIDs Throughout this package insert, the term NSAID refers to a non-aspirin non-steroidal anti-inflammatory drug. ) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see WARNINGS and PRECAUTIONS ]. Nabumetone is contraindicated in the setting of coronary artery bypass graft (CAB
Common side effects
- Diarrhea
- Dyspepsia
- Abdominal pain
- Constipation
- Flatulence
- Nausea
- Dizziness
- Headache
- Fatigue
- Rash
- Edema
- Dry mouth
Serious adverse events
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Anaphylaxis
- Myocardial infarction
- Renal failure
- Hepatic failure
- Gastrointestinal bleeding
- Gastric ulcer
- Duodenal ulcer
- Pancreatitis
Key clinical trials
- Effect of the Bioheat Patch on Pain Following the HyFoSy Procedure (NA)
- Acute Appendicitis: Active Observation With and Without Antibiotics (PHASE4)
- Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's Under Fasting Conditions (PHASE1)
- Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's Under Fed Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |